Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Conforti

Showing results (31-40 of 101) with videos related to

Pageof 11
Sort By:
Cancer Cell|June 24, 2022
Sex and cancer immunotherapy: Current understanding and challengesLaura Pala, Tommaso De Pas, Chiara Catania, et al.
Cancer Investigation|October 30, 2020
Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the LiteratureLaura Pala, Fabio Conforti, Emilia Cocorocchio, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2022
Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in ItalyChiara Corti, Fabio Conforti, Laura Pala, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2019
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trialFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Therapeutic Advances in Medical Oncology|December 4, 2020
Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centersMaristella Saponara, Laura Pala, Fabio Conforti, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2026
"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"Fabio Conforti, Isabella Sala, Laura Pala, et al.
Critical Reviews in Oncology/Hematology|October 26, 2013
Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic optionsChiara Lazzari, Gianluca Spitaleri, Chiara Catania, et al.
Current Oncology (Toronto, Ont.)|March 28, 2023
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature ReviewNunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2013
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lungFabio Conforti, Chiara Catania, Francesca Toffalorio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 23, 2015
Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumorsFrancesca Toffalorio, Filippo de Marinis, Fabio Conforti, et al.
Pageof 11

Showing results (31-40 of 101) with videos related to

Sort By:
Pageof 11
Cancer Cell|June 24, 2022
Sex and cancer immunotherapy: Current understanding and challengesLaura Pala, Tommaso De Pas, Chiara Catania, et al.
Cancer Investigation|October 30, 2020
Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the LiteratureLaura Pala, Fabio Conforti, Emilia Cocorocchio, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2022
Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in ItalyChiara Corti, Fabio Conforti, Laura Pala, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2019
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trialFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Therapeutic Advances in Medical Oncology|December 4, 2020
Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centersMaristella Saponara, Laura Pala, Fabio Conforti, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2026
"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"Fabio Conforti, Isabella Sala, Laura Pala, et al.
Critical Reviews in Oncology/Hematology|October 26, 2013
Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic optionsChiara Lazzari, Gianluca Spitaleri, Chiara Catania, et al.
Current Oncology (Toronto, Ont.)|March 28, 2023
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature ReviewNunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2013
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lungFabio Conforti, Chiara Catania, Francesca Toffalorio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 23, 2015
Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumorsFrancesca Toffalorio, Filippo de Marinis, Fabio Conforti, et al.
Pageof 11